Alogliptin in the treatment of type 2 diabetes mellitus: an evidence base for the clinical use


DOI: https://dx.doi.org/10.18565/pharmateca.2018.11.17-24

E.V. Biryukova

A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
Type 2 diabetes is a serious disease associated with the development of severe complications. The current treatment, including the use of drugs based on the “incretin effects”, and the mechanism of action of dipeptidyl peptidase-4 inhibitors are discussed. The results of clinical studies of the efficacy and safety of alogliptin are presented.
Keywords: type 2 diabetes mellitus, cardiovascular diseases, hypoglycemic therapy, dipeptidyl peptidase-4 inhibitors, alogliptin

About the Autors


Corresponding author: Elena V. Biryukova, MD, Professor, Department of Endocrinology and Diabetology, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia; e-mail: lena@obsudim.ru; ORCID: https://orcid.org/0000-0001-9007-4123
Address: 20, Build. 1, Delegatskaya Street, Moscow, 127473 Russian Federation


Бионика Медиа